Patents by Inventor Abbie G. Freeman

Abbie G. Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for producing therapeutically suitable glutaminase
    Patent number: 7052689
    Abstract: DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and when coupled to an anti-tumor monoclonal antibody is a potent anticancer agent. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: May 30, 2006
    Assignees: ME Medical Enzymes AG
    Inventors: Joseph Roberts, Thomas W MacAllister, Natarajan Sethuraman, Abbie G. Freeman
  • Genetically engineered glutaminase and its use in antiviral and anticancer therapy
    Publication number: 20020064862
    Abstract: DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and when coupled to an anti-tumor monoclonal antibody is a potent anticancer agent. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.
    Type: Application
    Filed: April 27, 2001
    Publication date: May 30, 2002
    Inventors: Joseph Roberts, Thomas W. MacAllister, Natarajan Sethuraman, Abbie G. Freeman
  • Genetically engineered glutaminase and its use in antiviral and anticancer therapy
    Patent number: 6312939
    Abstract: DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and when coupled to an anti-tumor monoclonal antibody is a potent anti-cancer agent. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: November 6, 2001
    Assignee: ME Medical Enzymes AG
    Inventors: Joseph Roberts, Thomas W MacAllister, Natarajan Sethuraman, Abbie G. Freeman